CD133 expression is possibly associated with worse prognosis in tumor patients [25] and has been used as a stem cell marker in various tumors including renal cell carcinoma, however, CD133 as a single marker may not be sufficient for CSC identification in RCC [16]. This evidence concerns the gene PROM1 and neoplasm.